Dr. Harmon's CV provides details of his role in supporting pharmaceutical drug candidates’ development efforts. One area of deep expertise is drug degradation, in particular understanding oxidative drug degradation pathways. Dr. Harmon authored the chapter on oxidative susceptibility testing in "Pharmaceutical Stress Testing" (2nd Edition; Eds. Baertschi, Alsante, Reed) and has eight other publications around oxidative degradation of drugs (references 8, 1, 5, 6, 10, 15-17, 19 in CV;PDF's available on page 2). Dr. Harmon is recognized as an industry expert in this field and has given invited talks at a variety of conferences around oxidation. The role of tablet excipients in producing new degradants, excipient enhancement of drug oxidation rates as well as excipient induced drug disproportionation have all be studied by Dr. Harmon (references 7, 13, 18, 19, 22 in CV). Most recently, Dr. Harmon has studied the mechanism of nitrosamine impurity formation in drug products
 
Over the last 5-10 years of his Merck & Co. Inc. experience, Dr. Harmon's efforts also focused on dissolution processes of enabled formulations and poorly soluble drug particles. Simple experimental approaches to measuring effective dissolution rates from the entire dosage form, in bio relevant dissolution media have been developed. Dr. Harmon has also detailed dissolution events occurring from amorphous solid dispersions (see dissolution related scientific publications 2, 3, 4, 9, and 12 in CV; PDF's available page 3). These detailed studies provide Dr. Harmon with valuable and unique insights into optimizing dissolution rates, thus optimizing human exposures of poorly water soluble drugs from pharmaceutical formulations.

In addition, below are links to PDF's of 6 other selected publications of Dr. Harmon, which reflect other aspects of his technical depth such as excipient induced drug disproportionation and isolation and identification of low level impurities.